Leverage is minimal with total debt of $6.3M and a D/E of 0.09 in 2026Q2, but retained earnings stand at -$434.7M against $72.3M of equity, indicating reliance on capital raised rather than accumulated profits.
Xilio Therapeutics, Inc. (XLO) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 126.5M | 145.03M | 60.23M | 48.13M | 124.5M | 202.52M | 20.59M | 51.1M |
| Cash & Short-Term Investments | 122.18M | 137.53M | 55.29M | 44.7M | 120.39M | 198.05M | 19.24M | 48.84M |
| Cash Only | 122.18M | 137.53M | 55.29M | 44.7M | 120.39M | 198.05M | 19.24M | 48.84M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 18.25 | 41.7 | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 2.5M | 4.94M | 3.42M | 4.11M | 4.46M | 0 | 1.01M |
| Total Non-Current Assets | 8.33M | 9.66M | 10.84M | 12.8M | 14.67M | 19.08M | 15.73M | 11.62M |
| Property, Plant & Equipment | 6.51M | 7.85M | 9.06M | 11.2M | 12.84M | 13.9M | 14.06M | 9.87M |
| Fixed Asset Turnover | 7.64x | 5.57x | 0.70x | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.81M | 1.81M | 1.78M | 0 | 1.56M | 1.55M | 0 | 194K |
| Other Non-Current Assets | 1.82M | 0 | 0 | 1.6M | 267K | 90K | 1.66M | 1.55M |
| Total Assets | 134.83M | 154.69M | 71.08M | 60.93M | 139.16M | 221.6M | 36.32M | 62.72M |
| Asset Turnover | 0.36x | 0.28x | 0.09x | - | - | - | - | - |
| Asset Growth % | 191.39% | 117.64% | 16.66% | -56.22% | -37.2% | 510.18% | -42.1% | - |
| Total Current Liabilities | 26.8M | 56.27M | 27.26M | 15.96M | 21.12M | 12.78M | 22.16M | 5.21M |
| Accounts Payable | 753K | 3.17M | 2.57M | 1.05M | 3.13M | 3.14M | 5.44M | 2.52M |
| Days Payables Outstanding | 1.94K | 750.37 | - | - | - | 765.55 | 1.87K | 3.83K |
| Short-Term Debt | 0 | 0 | 0 | 3.31M | 6.67M | 883K | 2.33M | 0 |
| Deferred Revenue (Current) | 109.58M | 40.02M | 13.52M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 5.73M | 4.21M | 4.74M | 82K | 3.61M | 0 | 1.92M |
| Current Ratio | 4.72x | 2.58x | 2.21x | 3.02x | 5.89x | 15.85x | 0.93x | 9.81x |
| Quick Ratio | 4.72x | 2.58x | 2.21x | 3.02x | 5.89x | 15.85x | 0.93x | 9.81x |
| Cash Conversion Cycle | -1.92K | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 39.8M | 63.14M | 26.22M | 8.14M | 12.4M | 23.39M | 19.45M | 19M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 3.17M | 9.63M | 7.81M | 9.61M |
| Capital Lease Obligations | 14.98M | 5.61M | 6.95M | 8.14M | 9.19M | 10.22M | 11.1M | 9.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 3.54M | 0 | 0 |
| Other Non-Current Liabilities | 25.38M | 57.53M | 0 | 0 | 45K | 0 | 540K | 374K |
| Total Liabilities | 66.6M | 119.41M | 53.48M | 24.1M | 33.52M | 36.17M | 41.6M | 24.21M |
| Total Debt | 5.96M | 6.95M | 8.14M | 12.5M | 19.94M | 20.74M | 21.89M | 18.63M |
| Net Debt | -116.22M | -130.58M | -47.15M | -32.2M | -100.45M | -177.32M | 2.65M | -30.21M |
| Debt / Equity | 0.09x | 0.20x | 0.46x | 0.34x | 0.19x | 0.11x | - | 0.48x |
| Debt / EBITDA | -0.15x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.92x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -596.45x | - | - | -125.33x | -91.03x | - |
| Total Equity | 68.23M | 35.27M | 17.6M | 36.83M | 105.65M | 185.43M | -5.29M | 38.51M |
| Equity Growth % | 2543.61% | 100.44% | -52.21% | -65.14% | -43.03% | 3608.59% | -113.72% | - |
| Book Value per Share | 3.47 | 4.22 | 4.60 | 18.75 | 53.98 | 463.05 | -141.26 | 1317.21 |
| Total Shareholders' Equity | 68.23M | 35.27M | 17.6M | 36.83M | 105.65M | 185.43M | -5.29M | 38.51M |
| Common Stock | 25.38M | 36.89M | 5K | 3K | 3K | 3K | 0 | 0 |
| Retained Earnings | -440.64M | -418.79M | -383.75M | -325.51M | -249.11M | -160.89M | -85.09M | -29.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying XLO stock.
As of 2025, Xilio Therapeutics, Inc. (XLO) had total assets of $154.7M including $145.0M in current assets.
Xilio Therapeutics, Inc. (XLO) carries total debt of $7.0M, offset by $137.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Xilio Therapeutics, Inc. (XLO) has total shareholders' equity (book value) of $35.3M ($4.22 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Xilio Therapeutics, Inc. (XLO) reported a current ratio of 2.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Cash runway dependent on financing
Metrics are mathematically derived from official filings.
Balance Sheet Rebuilt Through Cash Inflows
Based on reported figures, XLO's total assets rose from $82.6M in 2024Q1 to $154.3M in 2026Q2, with cash climbing to $136.0M, a pattern that points to episodic capital and collaboration inflows rather than self-funded expansion.
The asset build is almost entirely cash, which suggests the balance sheet strengthening reflects financing and milestone receipts rather than improving operating economics. Equity swung negative to -$8.1M in 2025Q3 before recovering to $72.3M, a volatility that warrants investors' attention to the durability of the funding base. The trajectory therefore reads as improving liquidity against a still-unproven earnings base.
Minimal Debt Keeps Leverage Largely Irrelevant
As reported in the balance sheet, XLO's total debt has drifted down from $8.9M to $6.3M over ten quarters, leaving a D/E ratio near 0.09 in 2026Q2 that is low in absolute terms.
Debt is a modest and declining share of the capital structure, so refinancing risk appears limited relative to the cash balance. The more relevant constraint is that total liabilities of $82.0M exceed debt several times over, implying that operating and deferred obligations, not borrowings, drive the liability side. Leverage is therefore not the binding balance sheet concern.
Cash Covers Liabilities With Ample Margin
Based on EDBL-style reporting conventions applied to XLO's figures, the current ratio of 4.25 in 2026Q2 and cash of $136.0M against $82.0M of total liabilities indicate a substantial near-term buffer.
Liquidity appears strong on a point-in-time basis, but the current ratio fell from 3.59 in 2026Q1 and the cash balance dropped from $150.3M over the same quarter, consistent with ongoing consumption. The relevant question is how long this cash lasts given persistent operating losses, and the supplied data does not include a runway estimate. Investors should monitor quarterly burn against the cash balance.
Accumulated Deficit Dwarfs Paid-In Capital
As reported in the balance sheet, retained earnings stood at -$434.7M in 2026Q2 against total equity of $72.3M, showing that the equity base is supported by capital raised rather than accumulated profits.
The persistent deficit, which has deepened every quarter from -$342.7M in 2024Q1, reflects a long history of operating losses funded externally. Equity quality is therefore dependent on continued capital access, and dilution is a plausible consequence of future raises. Investors should treat equity value as contingent on pipeline progress rather than earnings power.
Deferred Revenue May Overstate Cash Stability
Based on reported figures, deferred revenue of $35.3M in 2026Q2 after swinging between $26.5M and $79.0M over the period suggests that a meaningful share of the cash balance may be tied to unearned obligations.
If the $136.0M cash position includes customer prepayments that will be recognized as revenue rather than retained as free cash, the effective liquidity buffer would be smaller than headline cash suggests. The swings in deferred revenue indicate that milestone timing, not steady cash generation, drives the balance. This inference warrants further investigation into the contract terms underlying these balances.